title: Effect of abciximab on the levels of circulating microparticles in patients with acute myocardial infarction treated by primary angioplasty.
abstract: OBJECTIVE
  We investigated the effect of the additional use of abciximab during percutaneous coronary intervention (PCI) on the level of procoagulant microparticles (MPs) in patients with ST-segment elevation myocardial infarction (STEMI) who had undergone primary PCI.
  
  
  METHODS
  In this study, we studied 86 patients with STEMI (72 men, age 58±13) who had undergone primary PCI. The decision to administer abciximab immediately prior to PCI was left to the discretion of the operator. Blood samples for analysis of MPs were obtained from the femoral artery before and after PCI. MPs with procoagulant potential were measured using a commercial kit. The cellular origins of MPs were determined by antigenic capture with specific antibodies.
  
  
  RESULTS
  Procoagulant MPs captured onto annexin V were not changed significantly after PCI {13.4±13.2 nM vs. 13.2±16.1 nM phosphatidylserine equivalent (PS eq), p=0.479}. Abciximab was used in 30 of 86 patients (35%) immediately prior to PCI. In patients who had undergone PCI without abciximab, no significant change in the level of MPs was observed after PCI. However, in the abciximab group, the level of circulating MPs was significantly decreased after PCI (12.0±10.7 nM vs. 7.8±11.7 nM PS eq, p=0.018). Levels of endothelial- and platelet-derived MPs also showed a significant reduction after PCI in the abciximab group.
  
  
  CONCLUSIONS
  Primary PCI with additional abciximab significantly reduced the level of procoagulant MPs regardless of their cellular origins in patients with STEMI.
authors.affiliation: Cardiology Division, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
authors.forename: Jung-Joon
authors.initials: JJ
authors.lastname: Cha
authors.forename: Jong-Youn
authors.initials: JY
authors.lastname: Kim
authors.forename: Eui-Young
authors.initials: EY
authors.lastname: Choi
authors.forename: Pil-Ki
authors.initials: PK
authors.lastname: Min
authors.forename: Minhee
authors.initials: M
authors.lastname: Cho
authors.forename: Da-Lyung
authors.initials: DL
authors.lastname: Lee
authors.forename: Sung-Yu
authors.initials: SY
authors.lastname: Hong
authors.forename: Young-Won
authors.initials: YW
authors.lastname: Yoon
authors.forename: Byoung Kwon
authors.initials: BK
authors.lastname: Lee
authors.forename: Bum-Kee
authors.initials: BK
authors.lastname: Hong
authors.forename: Se-Joong
authors.initials: SJ
authors.lastname: Rim
authors.forename: Hyuck Moon
authors.initials: HM
authors.lastname: Kwon
keywords: Cell-derived microparticles; Myocardial infarction; Platelet aggregation inhibitors